Zhou Zhao, Qin Hui, Weng Lixin, Ni Yijiang
Department of General Surgery and 2ICU, the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, China.
J BUON. 2019 Mar-Apr;24(2):615-621.
To explore the therapeutic efficacy and safety of the combination treatment of dendritic cells and cytokine-induced killers (DC-CIK) and sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Patients diagnosed with advanced HCC and treated with DC-CIK and/or sorafenib in the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University from January 2015 to January 2016 were retrospectively analyzed. HCC patients were divided into (A): control group (oral administration of sorafenib) and (B): observation group (oral administration of sorafenib combined with DC-CIK). Patients were followed up every 4-8 weeks. Overall survival and adverse events of each patient were recorded. Therapeutic efficacy was evaluated using the modified RECIST criteria.
After treatment, ALT and TBIL were remarkably elevated in the control group and decreased in the observation group. No significant change in AFP level was seen in the control group after treatment, whereas it was remarkably decreased in the observation group. The efficacy rate was 16.7% and 51.4% in the control and observation group, respectively. Clinical benefit rate (CBR) was 41.9% and 88.6% in the control group and observation group, respectively. The median survival time of the control and observation group was 13.8 and 18.6 months, respectively. In the observation group there was a significant difference in the survival time between patients with Child-Pugh A and Child-Pugh B, respectively.
DC-CIK combined with sorafenib could improve the tumor response rate and prolong overall survival of advanced HCC without increasing the incidence of adverse events. HCC patients achieve a more stable disease condition and longer overall survival with DC-CIK combined with sorafenib than those with individual sorafenib treatment.
探讨树突状细胞与细胞因子诱导的杀伤细胞联合治疗（DC-CIK）及索拉非尼治疗晚期肝细胞癌（HCC）患者的疗效及安全性。
回顾性分析2015年1月至2016年1月在南京医科大学附属常州第二人民医院诊断为晚期HCC并接受DC-CIK和/或索拉非尼治疗的患者。HCC患者分为（A）对照组（口服索拉非尼）和（B）观察组（口服索拉非尼联合DC-CIK）。每4-8周对患者进行随访。记录每位患者的总生存期和不良事件。采用改良的RECIST标准评估治疗效果。
治疗后，对照组谷丙转氨酶（ALT）和总胆红素（TBIL）显著升高，观察组则下降。对照组治疗后甲胎蛋白（AFP）水平无显著变化，而观察组显著下降。对照组和观察组的有效率分别为16.7%和51.4%。对照组和观察组的临床获益率（CBR）分别为41.9%和88.6%。对照组和观察组的中位生存期分别为13.8个月和18.6个月。观察组中，Child-Pugh A级和Child-Pugh B级患者的生存时间存在显著差异。
DC-CIK联合索拉非尼可提高晚期HCC的肿瘤缓解率，延长总生存期，且不增加不良事件的发生率。与单独使用索拉非尼治疗相比，DC-CIK联合索拉非尼治疗的HCC患者病情更稳定，总生存期更长。
